Lasmiditan is in phase 3 clinical trials for treatment of acute migraine headaches. Lasmiditan is a selective serotonin receptor 5-HT1F agonist, which is centrally acting and penetrates the blood-brain barrier. It shows high affinity for the 5-HT1F receptor, which are found on trigeminal neurons, cortex, and cerebellum, and low affinity for 5-HT1B and 5- HT1D receptors. Studies suggest that a 5-HT1F agonist may act through direct neural mechanisms in the trigeminal system without vasoconstrictive side effects seen with 5-HT1B activation by triptan drugs. Lasmiditan is designed to block the activation of the trigeminal nerve pathway that transmits the sensation of headache pain and to block neurogenic inflammation of the meninges, believed to contribute to migraine headache pain.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL monograph for this compound, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.